Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
714 articles by Ben Fidler
-
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
Jan. 28, 2025 -
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors
Jan. 23, 2025 -
Sionna, Odyssey join queue of biotechs testing investors’ IPO interest
Jan. 21, 2025 -
‘The bar has risen’: China’s biotech gains push US companies to adapt
Jan. 16, 2025 -
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
Jan. 14, 2025 -
5 questions facing emerging biotech in 2025
Jan. 14, 2025 -
JPM25: Deals, Summit’s bravado and gene therapy headwinds
Jan. 13, 2025 -
Lilly pads cancer drug pipeline with Scorpion deal
Jan. 13, 2025 -
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
Jan. 10, 2025 -
IGM’s autoimmune pivot backfires as top drug disappoints in testing
Jan. 9, 2025 -
5 FDA decisions to watch in the first quarter of 2025
Jan. 6, 2025 -
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
Jan. 2, 2025 -
Ottimo raises $140M to compete in chase for new type of cancer drug
Dec. 19, 2024 -
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Dec. 17, 2024 -
FDA flags additional injury risk for Intercept’s liver drug
Dec. 12, 2024 -
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
Dec. 10, 2024 -
ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
Dec. 9, 2024 -
Dimension gets $500M to bankroll biotech’s convergence with tech
Dec. 9, 2024 -
Janux impresses Wall Street with new prostate cancer drug results
Dec. 3, 2024 -
Biohaven muscle drug misses goal of SMA study, but advances in obesity
Nov. 25, 2024 -
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov. 22, 2024 -
Biotech startups are built on venture capital. Track funding rounds here.
Nov. 21, 2024 -
Incyte sinks on setback for drugs acquired in $750M buyout
Nov. 19, 2024 -
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
Nov. 18, 2024 -
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
Nov. 14, 2024